Kepa B Uribe

List of Publications by Year in Descending Order

34 papers	592 citations	12 h-index	24 g-index
44 ext. papers	1,025 ext. citations	5.7 avg, IF	4.09 L-index

#	Paper	IF	Citations
34	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple-Cell 2D Atherosclerosis Model.. *Small*, **2022**, e2105915	11	1
33	Familial hypercholesterolemia **2022**, 501-524		
32	MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of Missense Variants. *JACC Basic To Translational Science*, **2021**, 6, 815-827	8.7	0
31	Evaluation of Multifunctional Gold Nanorods for Boron Neutron Capture and Photothermal Therapies. *ACS Applied Materials & Interfaces*, **2021**, 13, 49589-49601	9.5	4
30	Cholesterol stimulates the lytic activity of Adenylate Cyclase Toxin on lipid membranes by promoting toxin oligomerization and formation of pores with a greater effective size. *FEBS Journal*, **2021**, 288, 6795-6814	5.7	0
29	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 934-943	9.4	3
28	Pre-targeting with ultra-small nanoparticles: boron carbon dots as drug candidates for boron neutron capture therapy. *Journal of Materials Chemistry B*, **2021**, 9, 410-420	7.3	7
27	Molecular mechanisms of lipotoxicity-induced pancreatic □cell dysfunction. *International Review of Cell and Molecular Biology*, **2021**, 359, 357-402	6	6
26	(r)HDL in theranostics: how do we apply HDL□ biology for precision medicine in atherosclerosis management?. *Biomaterials Science*, **2021**, 9, 3185-3208	7.4	1
25	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants.. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	4
24	Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	16
23	Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. *Scientific Reports*, **2020**, 10, 1727	4.9	12
22	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. *Biomedicines*, **2020**, 8,	4.8	5
21	miR-27b Modulates Insulin Signaling in Hepatocytes by Regulating Insulin Receptor Expression. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
20	Pathophysiology of Type 2 Diabetes Mellitus. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	222
19	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 2248-2260	9.4	33
18	Membrane Permeabilization by Pore-Forming RTX Toxins: What Kind of Lesions Do These Toxins Form?. *Toxins*, **2019**, 11,	4.9	16

List of Publications

17	Membrane Permeabilization by Adenylate Cyclase Toxin Involves Pores of Tunable Size. *Biomolecules*, **2019**, 9,	5.9	6
16	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. *Atherosclerosis*, **2019**, 289, 162-172	3.1	12
15	Site-specific -glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. *Journal of Biological Chemistry*, **2018**, 293, 7408-7422	5.4	38
14	Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	22
13	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	36
12	p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro. *Scientific Reports*, **2018**, 8, 16614	4.9	3
11	Replacement of cysteine at position 46 in the first cysteine-rich repeat of the LDL receptor impairs apolipoprotein recognition. *PLoS ONE*, **2018**, 13, e0204771	3.7	
10	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. *Atherosclerosis*, **2017**, 263, 163-170	3.1	4
9	The leucine stretch length of PCSK9 signal peptide and its role in development of autosomal dominant hypercholesterolaemia: Unravelling the activities of P.LEU23DEL and P.LEU22_LEU23DUP variants. *Atherosclerosis*, **2017**, 263, e37	3.1	3
8	Phospholipase A activity of adenylate cyclase toxin mediates translocation of its adenylate cyclase domain. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E6784-E6793	11.5	18
7	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. *Scientific Reports*, **2017**, 7, 15282	4.9	24
6	Understanding the Mechanism of Translocation of Adenylate Cyclase Toxin across Biological Membranes. *Toxins*, **2017**, 9,	4.9	7
5	Adenylate Cyclase Toxin promotes bacterial internalisation into non phagocytic cells. *Scientific Reports*, **2015**, 5, 13774	4.9	8
4	Calpain-Mediated Processing of Adenylate Cyclase Toxin Generates a Cytosolic Soluble Catalytically Active N-Terminal Domain. *PLoS ONE*, **2013**, 8, e67648	3.7	15
3	Ca2+ influx and tyrosine kinases trigger Bordetella adenylate cyclase toxin (ACT) endocytosis. Cell physiology and expression of the CD11b/CD18 integrin major determinants of the entry route. *PLoS ONE*, **2013**, 8, e74248	3.7	5
2	Functional characterization of splicing and ligand-binding domain variants in the LDL receptor. *Human Mutation*, **2012**, 33, 232-43	4.7	33
1	Adenylate cyclase toxin promotes internalisation of integrins and raft components and decreases macrophage adhesion capacity. *PLoS ONE*, **2011**, 6, e17383	3.7	12